Alloy Therapeutics Series E — Alloy Therapeutics

Alloy Therapeutics has secured $40 million in a Series E financing round, valuing the company at $1 billion. This funding marks a transition for Alloy from an antibody discovery company to a full-stack biotech infrastructure provider. The capital will fuel further development of their AI-driven platforms and integrated services, aiming to accelerate drug discovery and development.